---
title: ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific
  Anti-HLA Antibodies
date: '2024-09-11'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39260570/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1Rkszs2HVZ2RHP33OibaNFew6VK-LzjJWTD4GwmLlk8B-wCceh&fc=20220923065203&ff=20240912194138&v=2.18.0.post9+e462414
source: (((leukemia) OR (lymphoma)) OR (myeloma)) AND (Stanford University[Affiliation])
description: Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment
  failure and may negatively impact survival outcomes of patients receiving allogeneic
  hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft.
  The incidence of DSA varies across studies, depending on individual factors, detection
  or identification methods and thresholds considered clinically relevant. Although
  DSA testing by multiplex bead arrays remains semiquantitative, it has been ...
disable_comments: true
---
Donor-specific anti-HLA antibodies (DSA) are an important cause of engraftment failure and may negatively impact survival outcomes of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) using an HLA-mismatched allograft. The incidence of DSA varies across studies, depending on individual factors, detection or identification methods and thresholds considered clinically relevant. Although DSA testing by multiplex bead arrays remains semiquantitative, it has been ...